Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
- PMID: 35163019
- PMCID: PMC8834928
- DOI: 10.3390/ijms23031096
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
Abstract
Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.
Keywords: chemotherapy; chondrosarcoma; immunotherapy; therapeutic target.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26. Br J Cancer. 2018. PMID: 29576625 Free PMC article.
-
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.Am Soc Clin Oncol Educ Book. 2015:e648-55. doi: 10.14694/EdBook_AM.2015.35.e648. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993236 Review.
-
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300. Curr Opin Oncol. 2016. PMID: 27166664 Review.
-
High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.Int J Mol Sci. 2024 Dec 3;25(23):13003. doi: 10.3390/ijms252313003. Int J Mol Sci. 2024. PMID: 39684713 Free PMC article.
-
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12. Oncogene. 2019. PMID: 31406254
Cited by
-
Chondrosarcoma With Pulmonary Metastatic Calcifications: A Case Report and Review of the Literature.Cureus. 2024 Jan 30;16(1):e53234. doi: 10.7759/cureus.53234. eCollection 2024 Jan. Cureus. 2024. PMID: 38425591 Free PMC article.
-
DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer.Medicine (Baltimore). 2025 Feb 14;104(7):e41578. doi: 10.1097/MD.0000000000041578. Medicine (Baltimore). 2025. PMID: 39960919 Free PMC article.
-
Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.BMC Cancer. 2025 May 9;25(1):852. doi: 10.1186/s12885-025-14281-y. BMC Cancer. 2025. PMID: 40346495 Free PMC article.
-
Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment.Int J Mol Sci. 2022 Sep 10;23(18):10509. doi: 10.3390/ijms231810509. Int J Mol Sci. 2022. PMID: 36142424 Free PMC article. Review.
-
Surgical Treatment of Bone Sarcoma.Cancers (Basel). 2022 May 29;14(11):2694. doi: 10.3390/cancers14112694. Cancers (Basel). 2022. PMID: 35681674 Free PMC article. Review.
References
-
- WHO Classification of Tumours Editorial Board . WHO Classification of Tumours of Soft Tissue and Bone. 5th ed. IARC Press; Lyon, France: 2020.
-
- Limaiem F., Davis D.D., Sticco K.L. Chondrosarcoma. StatPearls Publishing; Treasure Island, FL, USA: 2022. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous